{"preliminary_commentary":{"by_channel":{"youtube":6,"x_thread":6,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06750094\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"OrigAMI-3","nct_id":"NCT06750094","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=origami-3-nct06750094. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"OrigAMI-3","arms":[{"description":"Participants will receive amivantamab along with FOLFIRI (consisting of 5-fluorouracil, leucovorin calcium \\[folinic acid\\] or levoleucovorin, and irinotecan) as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.","label":"Arm A: Amivantamab + FOLFIRI","type":"EXPERIMENTAL"},{"description":"Participants will receive either cetuximab or bevacizumab along with FOLFIRI as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.","label":"Arm B: Cetuximab or Bevacizumab + FOLFIRI","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-04-13","type":"ESTIMATED"},"conditions":["Colorectal Neoplasms"],"enrollment":{"count":700,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Amivantamab","otherNames":["JNJ-61186372"],"type":"BIOLOGICAL"},{"name":"Cetuximab","otherNames":["Erbitux"],"type":"BIOLOGICAL"},{"name":"Bevacizumab","otherNames":["Avastin"],"type":"BIOLOGICAL"},{"name":"5-fluorouracil","otherNames":[],"type":"DRUG"},{"name":"Leucovorin calcium/Levoleucovorin","otherNames":["Folinic acid"],"type":"DRUG"},{"name":"Irinotecan","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-12-15","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to 2 years 1 month"},{"measure":"Overall Survival (OS)","timeFrame":"Up to 4 years 4 months"}],"references":[],"start_date":{"date":"2024-12-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","url":"https://clinicaltrials.gov/study/NCT06750094"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/origami-3-nct06750094"}